Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation

Mary E. Fidler, James M. Gloor, Donna J. Lager, Timothy S. Larson, Matthew D. Griffin, Stephen C Textor, Thomas R. Schwab, Mikel Prieto, Scott Nyberg, Michael B. Ishitani, Joseph Peter Grande, Paul A. Kay, Mark D Stegall

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The purpose of this study was to characterize the histology of antibody-mediated rejection (AMR) in ABO blood-group-incompatible (ABOI) kidney transplants as well as on protocol biopsies performed at the time of stable allograft function. Between 5/99 and 1/02, we performed 32 ABOI kidney transplants (13 A2, 19 non-A2 blood-group living donors). Nineteen biopsies were performed for allograft dysfunction, and 127 protocol biopsies were performed 0, 3, 7, 14, 28 days and 3 and 12 months post transplant. Twenty-five of 32 patients have functioning allografts (mean 585 days post transplant). Nine of 32 (28%) developed clinical AMR. Biopsy revealed glomerular thrombi (78%), mesangiolysis (78%), peritubular capillary C4d staining (56%) and neutrophil infiltration (67%), interstitial hemorrhage and necrosis (56%) and arteriolar thrombi (33%). Subclinical AMR was diagnosed by protocol biopsies in four patients. Findings consisted of glomerular thrombi (100%), mesangiolysis (25%), and C4d staining (100%). In late protocol biopsies performed 214-420 days post transplant, mild mesangiolysis was seen in 2/17 (11.7%), and C4d immunostaining was detected in 3/12 (25%). AMR is characterized by glomerular thrombi, mesangiolysis, peritubular capillary neutrophil infiltration interstitial hemorrhage, necrosis, and C4d deposition. Glomerular thrombi appear early in AMR and may appear prior to graft dysfunction.

Original languageEnglish (US)
Pages (from-to)101-107
Number of pages7
JournalAmerican Journal of Transplantation
Volume4
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Living Donors
Blood Group Antigens
Kidney Transplantation
Thrombosis
Transplants
Biopsy
Antibodies
Allografts
Neutrophil Infiltration
varespladib methyl
Necrosis
Staining and Labeling
Hemorrhage
Kidney
Histology

Keywords

  • ABO blood group
  • Antibodies
  • Blood group incompatibility
  • Graft rejection
  • Kidney transplant

ASJC Scopus subject areas

  • Immunology

Cite this

Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation. / Fidler, Mary E.; Gloor, James M.; Lager, Donna J.; Larson, Timothy S.; Griffin, Matthew D.; Textor, Stephen C; Schwab, Thomas R.; Prieto, Mikel; Nyberg, Scott; Ishitani, Michael B.; Grande, Joseph Peter; Kay, Paul A.; Stegall, Mark D.

In: American Journal of Transplantation, Vol. 4, No. 1, 01.2004, p. 101-107.

Research output: Contribution to journalArticle

Fidler, Mary E. ; Gloor, James M. ; Lager, Donna J. ; Larson, Timothy S. ; Griffin, Matthew D. ; Textor, Stephen C ; Schwab, Thomas R. ; Prieto, Mikel ; Nyberg, Scott ; Ishitani, Michael B. ; Grande, Joseph Peter ; Kay, Paul A. ; Stegall, Mark D. / Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation. In: American Journal of Transplantation. 2004 ; Vol. 4, No. 1. pp. 101-107.
@article{6e556372800845d892339869eed3a9b0,
title = "Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation",
abstract = "The purpose of this study was to characterize the histology of antibody-mediated rejection (AMR) in ABO blood-group-incompatible (ABOI) kidney transplants as well as on protocol biopsies performed at the time of stable allograft function. Between 5/99 and 1/02, we performed 32 ABOI kidney transplants (13 A2, 19 non-A2 blood-group living donors). Nineteen biopsies were performed for allograft dysfunction, and 127 protocol biopsies were performed 0, 3, 7, 14, 28 days and 3 and 12 months post transplant. Twenty-five of 32 patients have functioning allografts (mean 585 days post transplant). Nine of 32 (28{\%}) developed clinical AMR. Biopsy revealed glomerular thrombi (78{\%}), mesangiolysis (78{\%}), peritubular capillary C4d staining (56{\%}) and neutrophil infiltration (67{\%}), interstitial hemorrhage and necrosis (56{\%}) and arteriolar thrombi (33{\%}). Subclinical AMR was diagnosed by protocol biopsies in four patients. Findings consisted of glomerular thrombi (100{\%}), mesangiolysis (25{\%}), and C4d staining (100{\%}). In late protocol biopsies performed 214-420 days post transplant, mild mesangiolysis was seen in 2/17 (11.7{\%}), and C4d immunostaining was detected in 3/12 (25{\%}). AMR is characterized by glomerular thrombi, mesangiolysis, peritubular capillary neutrophil infiltration interstitial hemorrhage, necrosis, and C4d deposition. Glomerular thrombi appear early in AMR and may appear prior to graft dysfunction.",
keywords = "ABO blood group, Antibodies, Blood group incompatibility, Graft rejection, Kidney transplant",
author = "Fidler, {Mary E.} and Gloor, {James M.} and Lager, {Donna J.} and Larson, {Timothy S.} and Griffin, {Matthew D.} and Textor, {Stephen C} and Schwab, {Thomas R.} and Mikel Prieto and Scott Nyberg and Ishitani, {Michael B.} and Grande, {Joseph Peter} and Kay, {Paul A.} and Stegall, {Mark D}",
year = "2004",
month = "1",
doi = "10.1046/j.1600-6135.2003.00278.x",
language = "English (US)",
volume = "4",
pages = "101--107",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation

AU - Fidler, Mary E.

AU - Gloor, James M.

AU - Lager, Donna J.

AU - Larson, Timothy S.

AU - Griffin, Matthew D.

AU - Textor, Stephen C

AU - Schwab, Thomas R.

AU - Prieto, Mikel

AU - Nyberg, Scott

AU - Ishitani, Michael B.

AU - Grande, Joseph Peter

AU - Kay, Paul A.

AU - Stegall, Mark D

PY - 2004/1

Y1 - 2004/1

N2 - The purpose of this study was to characterize the histology of antibody-mediated rejection (AMR) in ABO blood-group-incompatible (ABOI) kidney transplants as well as on protocol biopsies performed at the time of stable allograft function. Between 5/99 and 1/02, we performed 32 ABOI kidney transplants (13 A2, 19 non-A2 blood-group living donors). Nineteen biopsies were performed for allograft dysfunction, and 127 protocol biopsies were performed 0, 3, 7, 14, 28 days and 3 and 12 months post transplant. Twenty-five of 32 patients have functioning allografts (mean 585 days post transplant). Nine of 32 (28%) developed clinical AMR. Biopsy revealed glomerular thrombi (78%), mesangiolysis (78%), peritubular capillary C4d staining (56%) and neutrophil infiltration (67%), interstitial hemorrhage and necrosis (56%) and arteriolar thrombi (33%). Subclinical AMR was diagnosed by protocol biopsies in four patients. Findings consisted of glomerular thrombi (100%), mesangiolysis (25%), and C4d staining (100%). In late protocol biopsies performed 214-420 days post transplant, mild mesangiolysis was seen in 2/17 (11.7%), and C4d immunostaining was detected in 3/12 (25%). AMR is characterized by glomerular thrombi, mesangiolysis, peritubular capillary neutrophil infiltration interstitial hemorrhage, necrosis, and C4d deposition. Glomerular thrombi appear early in AMR and may appear prior to graft dysfunction.

AB - The purpose of this study was to characterize the histology of antibody-mediated rejection (AMR) in ABO blood-group-incompatible (ABOI) kidney transplants as well as on protocol biopsies performed at the time of stable allograft function. Between 5/99 and 1/02, we performed 32 ABOI kidney transplants (13 A2, 19 non-A2 blood-group living donors). Nineteen biopsies were performed for allograft dysfunction, and 127 protocol biopsies were performed 0, 3, 7, 14, 28 days and 3 and 12 months post transplant. Twenty-five of 32 patients have functioning allografts (mean 585 days post transplant). Nine of 32 (28%) developed clinical AMR. Biopsy revealed glomerular thrombi (78%), mesangiolysis (78%), peritubular capillary C4d staining (56%) and neutrophil infiltration (67%), interstitial hemorrhage and necrosis (56%) and arteriolar thrombi (33%). Subclinical AMR was diagnosed by protocol biopsies in four patients. Findings consisted of glomerular thrombi (100%), mesangiolysis (25%), and C4d staining (100%). In late protocol biopsies performed 214-420 days post transplant, mild mesangiolysis was seen in 2/17 (11.7%), and C4d immunostaining was detected in 3/12 (25%). AMR is characterized by glomerular thrombi, mesangiolysis, peritubular capillary neutrophil infiltration interstitial hemorrhage, necrosis, and C4d deposition. Glomerular thrombi appear early in AMR and may appear prior to graft dysfunction.

KW - ABO blood group

KW - Antibodies

KW - Blood group incompatibility

KW - Graft rejection

KW - Kidney transplant

UR - http://www.scopus.com/inward/record.url?scp=0742301292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742301292&partnerID=8YFLogxK

U2 - 10.1046/j.1600-6135.2003.00278.x

DO - 10.1046/j.1600-6135.2003.00278.x

M3 - Article

C2 - 14678040

AN - SCOPUS:0742301292

VL - 4

SP - 101

EP - 107

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 1

ER -